Quantum BioPharma Takes On Neurological Disorders with Diversified Strategy
November 4, 2026 — Quantum BioPharma (NASDAQ: QNTM) advances a diversified strategy to tackle neurological disorders, targeting a market of over 3 billion people with its lead candidate Lucid-MS.